drugset
Drugs / KIVU-305
last change Jun 2026 re-read 3 minutes ago

KIVU-305

Other / unclassified targets CEACAM5

Developed for
cancer
Investigated by
Kivu Bioscience Inc.

Trials 1

today NCT07545356 · Ph 1
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07545356 Jun 2026 → Dec 2027 expected cancer Kivu Bioscience Inc. Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2026-04-14 Kivu Bioscience Inc. Results Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026 kivubioscience.com ↗
Next-generation CEACAM5 ADC KIVU-305 demonstrates potent preclinical activity and enhanced stability across colorectal and other solid tumor models
2026-02-25 Kivu Bioscience Inc. Regulatory Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial kivubioscience.com ↗
Kivu also announced another significant milestone with receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as KIVU-305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07545356 ↗
Modality Other / unclassified “a CEACAM5-directed antibody-drug conjugate” NCT07545356 ↗
Route Intravenous “KIVU-305 will be administered IV .” NCT07545356 ↗
Target CEACAM5 “CEACAM5-directed” NCT07545356 ↗